 |
BioWorld-International-2008-08-27
Novosom In-Licenses Antisense CD40 Inhibitors from Isis Pharma
Novosom In-Licenses Antisense CD40 Inhibitors from Isis Pharma
Novosom AG in-licensed from Isis Pharmaceuticals Inc. the rights to antisense inhibitors that target CD40 mRNA for several indications, including Crohn's disease, rheumatoid arthritis and organ transplant rejection. (BioWorld International)